H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $4 price target ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN: